Loading
A phase 2 trial of Mifamurtide and Ifosfamide in Osteosarcoma, run by University of Oxford, recorded as terminated on the registry.
A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS) is a phase 2 interventional study registered as NCT02441309 by University of Oxford, with 8 participants recorded, started 2014-10 and due to reach its primary completion in 2016-11-04. Interventions recorded: Mifamurtide, Ifosfamide. Conditions recorded: Osteosarcoma.
Linked to the drug Mifamurtide because the registry names it among its interventions and Osteosarcoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
8 enrolled.
95% CI 0.2 to NA; Figures from the ClinicalTrials.gov results section (first posted 2019-09-13), not from a publication · 95% CI 9.2 to NA · 95% CI 1.5 to NA
SourceNo events were observed, median is undefined.; Figures from the ClinicalTrials.gov results section (first posted 2019-09-13), not from a publication · No events were observed, median is undefined. · 95% CI 4.6 to NA
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Disease Specific Overall Survival | A. Mifamurtide Only | 3 | 0.7 months | - | - | link |
| B. Ifosfamide (Followed by Mifamurtide) | 2 | 9.2 months | ||||
| C. Ifosfamide + Mifamurtide | 3 | 2.8 months | ||||
| Progression Free Survival | A. Mifamurtide Only | 3 | No events were observed, median is undefined.; Figures from the ClinicalTrials.gov results section (first posted 2019-09-13), not from a publication | - | - | link |
| B. Ifosfamide (Followed by Mifamurtide) | 2 | No events were observed, median is undefined. | ||||
| C. Ifosfamide + Mifamurtide | 3 | 7 months |
Shares Mifamurtide, Osteosarcoma and the tag pipeline.
Shares Mifamurtide, Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Ifosfamide and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.